Cromolyn Disodium Salt CAS 15826-37-6
Introduction：Basic information about Cromolyn Disodium Salt CAS 15826-37-6, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Cromolyn Disodium Salt Basic informationDescription References
| Product Name: | Cromolyn Disodium Salt |
| Synonyms: | DSCG;DISODIUM CROMOGLYCATE;disodium 5,5'-[(2-hydroxytrimethylene)dioxy]bis[4-oxo-4h-1-benzopyran-2-carboxylate];disodium 1,3-bis(2-carboxy-5-chromonyloxy)-2-propanol;CROMOGLYCATE SODIUM SALT;CROMOGLYCIC ACID SODIUM SALT;CROMOLYN SODIUM;CROMOLYN SODIUM SALT |
| CAS: | 15826-37-6 |
| MF: | C23H17NaO11 |
| MW: | 492.37 |
| EINECS: | 239-926-7 |
| Product Categories: | INTAL;Other APIs;Intermediates & Fine Chemicals;Pharmaceuticals;Drug bulk;API |
| Mol File: | 15826-37-6.mol |
Cromolyn Disodium Salt Chemical Properties
| Melting point | 241-2420C (dec) |
| storage temp. | 2-8°C |
| solubility | Soluble in water, practically insoluble in ethanol (96 per cent). |
| form | Solid |
| color | White to Off-White |
| Water Solubility | Soluble in water to 100mg/ml |
| Merck | 14,2590 |
| Stability: | Hygroscopyc |
| Cosmetics Ingredients Functions | ANTI-SEBUM |
| InChIKey | VLARUOGDXDTHEH-UHFFFAOYSA-L |
| SMILES | O(C1C=CC=C2OC(C(=O)O)=CC(=O)C=12)CC(O)COC1C=CC=C2OC(C(=O)O)=CC(=O)C=12.[NaH] |
| CAS DataBase Reference | 15826-37-6(CAS DataBase Reference) |
Safety Information
| Hazard Codes | Xi |
| Risk Statements | 36/37/38 |
| Safety Statements | 26-36 |
| RIDADR | 3249 |
| WGK Germany | 2 |
| RTECS | DJ2380000 |
| HazardClass | 6.1(b) |
| PackingGroup | III |
| HS Code | 29329990 |
| Storage Class | 11 - Combustible Solids |
| Hazard Classifications | Eye Irrit. 2 Skin Irrit. 2 STOT SE 3 |
| Toxicity | LD50 in mice, rats (mg/kg): >8000 orally (Cox) |
| Description | Sodium cromoglycate is the sodium salt and common market from of cromoglicic acid, which is a synthetic compound, and as a mast cell stabilizer. It is capable of inhibiting the antigen-induced bronchospasms, and thus being used to treat the asthma and allergic rhinitis. It can also be applied as an ophthalmic solution for the treatment of conjunctivitis and systemic mastocytosis and ulcerative colitis. It is capable of inhibiting the degranulation of mast cells, further preventing the release of histamine and slow-reacting substance of anaphylaxis (SRS-A), the mediators of type I allergic reaction. It is also capable of inhibiting the release of inflammatory leukotrienes and inhibiting calcium influx. |
| References | https://www.drugbank.ca/drugs/DB01003 https://en.wikipedia.org/wiki/Cromoglicic_acid |
| Description | Disodium cromoglycateis a relatively nontoxic agent usedfor the long-term prevention of many types ofasthma. It has no bronchodilator propertiesand is used in the prophylaxis of asthma.It does not play a role in the treatment of acuteasthmatic attacks including severe asthma. |
| Chemical Properties | White Crystalline Powder |
| Originator | Intal,Fisons,UK,1969 |
| Uses | antiasthmatic, antiallergy |
| Uses | Anti Asthamatic |
| Uses | Chromone complex which blocks mast cell degranulation |
| Indications | Cromolyn sodium (Intal) is chemically related drugs called chromones that is used for the prophylaxis of mild or moderateasthma. It is administered by inhalation and has very good safety profiles, making them particularly usefulin treating children. |
| Definition | ChEBI: An organic sodium salt that is the disodium salt of cromoglycic acid. |
| Manufacturing Process | To a solution of 970 parts of 2,6-dihydroxyacetophenone and 325 parts ofepichlorohydrin in 1,500 parts of hot isopropanol was added, with stirring under reflux, a solution of 233 parts of 85% KOH in 2,500 parts ofisopropanol and sufficient water (ca 100 parts) to dissolve the solid. Themixture was heated, with stirring, under reflux for 48 hours. Half the solventwas then distilled off and 5,000 parts of water were added. The mixture wascooled and the solid filtered off and washed with isopropanol and ether. It wasthen recrystallized from 12,500 parts of isopropanol to obtain a first crop of380 parts and a second crop, after concentration, of 300 parts of 1,3-bis(2-acetyl-3-hydroxyphenoxy)-2hydroxypropane. 4.6 parts of 1,3-bis(2-acetyl-3-hydroxyphenoxy)-2-hydroxypropane werereacted with diethyl oxalate and the product cyclized to obtain 4.4 parts ofpure diethyl ester of 1,3-bis(2-carboxychromon-5-yloxy)-2-hydroxypropane aspale yellow crystals melting between 180° and 182°C from a mixture ofbenzene and petrol, 4 parts of the diethyl ester of 1,3-bis(2-carboxychromon5-yloxy)-2-hydroxypropane were saponified with sodium hydroxide to obtain3.2 parts of the disodium salt tetrahydrate as colorless crystals from aqueousalcohol. |
| Therapeutic Function | Bronchodilator |
| General Description | Cromolyn sodium, disodium 1,3-bis(2-carboxychromon-5-yloxy)-2-hydroxypropane (Intal), isa hygroscopic, white, hydrated crystalline powder that is solublein water (1:10). It is tasteless at first but leaves a veryslightly bitter aftertaste. The pK of cromolyn is 2. It is availableas a solution for a nebulizer, an aerosol spray, a nasal solution,an ophthalmic solution, and an oral concentrate. Nebulized and aerosol cromolyn has been used for prophylacticmanagement of bronchial asthma and prevention ofexercise-induced bronchospasm. Cromolyn nasal solution isused for the prevention and treatment of allergic rhinitis, andoral concentrate is used to treat the histaminic symptomsof mastocytosis (diarrhea, flushing, headaches, vomiting, urticaria,abdominal pain, nausea, and itching). Topical cromolyn(eye drops) is used to treat allergic conjunctivitis andkeratitis. In the treatment of asthma, cromolyn efficacy is manifestedby decreased severity of clinical symptoms, or need for concomitant therapy, or both. Long-term use is justified if thedrug significantly reduces the severity of asthma symptoms;permits a significant reduction in, or elimination of, steroiddosage; or improves management of those who have intolerableside effects to sympathomimetic agents or methylxanthines.For cromolyn to be effective, it must be administered atleast 30 minutes prior to antigen challenge and administered atregular intervals (see dosing information that follows). Wheninhaled, the powder does produce irritation in some patients.Also, overuse of cromolyn can result in tolerance. |
| Biochem/physiol Actions | Cromolyn blocks the release of histamine and other pro-inflammatory mediators from mast cells. |
| Mechanism of action | The precise mechanism or mechanisms whereby cromolynsodium and nedocromil sodium exert their antiasthmaticactivities is unknown. Early work suggestedthat these agents act by “stabilizing” mast cells, preventingmediator release. However, several other compoundsexhibit greater potency for stabilization of mastcells yet possess no clinical efficacy in asthma.This suggeststhat the therapeutic activity of cromolyn sodiumand nedocromil sodium in asthma is related to one ormore other pharmacological mechanisms. Postulates includeinhibitory effects on irritant receptors, nerves,plasma exudation, and inflammatory cells in general. |
| Pharmacokinetics | Cromolyn sodium is a bischromone that contains the fundamental benzopyrone moiety of khellin. The two chromone rings are necessary for activity and must be coplanar, with a linking chain of no longer than six carbons. If one changes the linking chain to positions 8 and 8′, coplanarity cannot be maintained, and the compound loses all activity. Cromolyn sodium is poorly absorbed from the lungs (~8%), insignificantly from the eye (~0.07%), and by approximately 1% from the GI tract. What little that finds its way into systemic circulation is eliminated intact in the urine and the bile. For the treatment of asthma, cromolyn sodium is available as a solution for both intranasal and inhalation administration. There also is an oral concentrate (100 mg/5 mL), which is administered as a 200-mg dose given four times a day. |
| Clinical Use | Cromolyn sodium is used almostexclusively for the prophylactic treatment of mildto moderate asthma and should not be used for the controlof acute bronchospasm. This agent is effectivein about 60 to 70% of children and adolescents withasthma. Unfortunately, there is no reliable means topredict which patients will respond.It is less effectivein older patients and in patients with severeasthma. It may take up to 4 to 6 weeks of treatment forcromolyn sodium to be effective in chronic asthma, butit is effective after a single dose in exercise-inducedasthma. With respect to clinical efficacy, cromolynsodium and nedocromil sodium do not differ in a substantialway. |
| Side effects | Cromolyn sodium is the leasttoxic of available therapies for asthma. Adverse reactionsare rare and generally minor. Those occurring infewer than 1 in 10,000 patients include transient bronchospasm,cough or wheezing, dryness of throat, laryngealedema, swollen parotid gland, angioedema, jointswelling and pain, dizziness, dysuria, nausea, headache,nasal congestion, rash, and urticaria. |
| storage | Store at RT |
Cromolyn Disodium Salt Preparation Products And Raw materials
| Raw materials | Isopropyl alcohol-->Diethyl oxalate-->Epichlorohydrin-->Resorcinol-->2',6'-Dihydroxyacetophenone-->Diethyl cromoglycate-->Sodium hydroxide |
